tiprankstipranks

Analyst Profile

Followed by 235 followers
.
Michael Higgins

Michael Higgins

Ladenburg Thalmann & Co.
Wall Street Analyst
#1,401 out of 7,961 Wall Street Analysts
#2,867 out of 22,230 experts

Success Rate

32%
132 out of 411 transactions made a profit

Average Return

+5.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Michael Higgins's trades since 2013 and holding each position for 1 Year would result in 32.12% of your transactions generating a profit, with an average return of 5.9% per rating.

Stock Rating Distribution

614Ratings
90.39% Buy
9.12% Hold
0.49% Sell
Distribution of Michael Higgins's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
CanadaCanadian Market
United KingdomUK Market

Best Rating

Stock:
Novavax
(NVAX)
Rating:Buy
Date:Mar 12, 2020 - Jul 08, 2020
Return:+800.00%
The most profitable rating made by Michael Higgins

Michael Higgins's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Cardiff Oncology
May 06, 2013
Buy
Initiated
$17.00
(1003.90% Upside)
1Ratings
0.00%
Titan Pharmaceuticals
Jul 07, 2014
Buy
Initiated
$3.00
(181.16% Upside)
1Ratings
0.00%
Evotec AG
Sep 17, 2014
Buy
Initiated
1Ratings
0.00%
Pieris Pharmaceuticals
Jul 22, 2015
Buy
Initiated
$7.00
(514.04% Upside)
1Ratings
0.00%
Acura Pharmaceuticals
Oct 18, 2016
Buy
Reiterated
$6.00
(59900.00% Upside)
2Ratings
0%
-62.90%
ACADIA Pharmaceuticals
Nov 28, 2016
Hold
Reiterated
$25.00
(53.56% Upside)
3Ratings
0.00%
SGYPQ
Synergy Pharmaceuticals Inc
Mar 10, 2017
Buy
Reiterated
12Ratings
0%
-57.10%
JNP
Juniper Pharmaceuticals
May 05, 2017
Buy
Reiterated
10Ratings
100%
+88.60%
Altamira Therapeutics
Jun 30, 2017
Buy
Initiated
$4.50
(1700.00% Upside)
1Ratings
0%
-89.00%
Trevena
Jul 21, 2017
Buy
Reiterated
$8.50
(5401.62% Upside)
10Ratings
0%
-53.63%
List of latest recommendations made by Michael Higgins. Click to expand and see Michael Higgins's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >